Stereotaxis Launches Interface between Niobe® ES System and Philips’ State-of-the-art X-ray System

ST. LOUIS, Dec. 14, 2016 -- Stereotaxis, Inc. (OTCQX:STXS), a global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced the release of an interface between its remote magnetic navigation system for electrophysiology (EP) procedures and the Philips Allura Xper FD10 cardiovascular x-ray system. The interface allows interoperability of the Stereotaxis Niobe^® system with the Philips Allura Xper FD10 version R8.2 system and is available worldwide.

“The seamless integration of our two platforms further optimizes EP procedures by providing state-of-the-art fluoroscopic visualization with enhanced managed x-ray doses,” said William C. Mills, Chief Executive Officer and Chairman. “The combination of our advanced technologies facilitates physicians in delivering therapy safely, quickly and accurately for the benefit of patients. We will continue to identify and build strategic alliances with industry leaders such as Philips to bring distinctive solutions to the practice of interventional medicine.”

The Allura Xper FD10 is a ceiling-suspended imaging system widely used for EP and other cardiac interventions. The system offers rotational scan for high-resolution 3D images of cardiac anatomy in real-time, managed x-ray, and storage and retrieval of multi-modality cardiology information.

About Stereotaxis
Stereotaxis is a healthcare technology and innovation leader in the development of robotic cardiology instrument navigation systems designed to enhance the treatment of arrhythmias and coronary disease, as well as information management solutions for the interventional lab. Over 100 issued patents support the Stereotaxis platform, which helps physicians around the world provide unsurpassed patient care with robotic precision and safety, improved lab efficiency and productivity, and enhanced integration of procedural information. Stereotaxis' core Epoch^® Solution includes the Niobe^® magnetic navigation system, the Odyssey^® portfolio of lab optimization, networking and patient information management solutions, and the Vdrive^® robotic navigation system and consumables.

The core components of Stereotaxis’ systems have received regulatory clearance in the United States, European Union, Canada, China, Japan, and elsewhere. The V-Sono™ ICE catheter manipulator, V-Loop™ variable loop catheter manipulator, and V-CAS™ catheter advancement system have received clearance in the United States, Canada, and the European Union. The V-CAS Deflect^™ catheter advancement system has been CE Marked for sale in the European Union. For more information, please visit www.stereotaxis.com.

This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to raise additional capital on a timely basis and on terms that are acceptable, its ability to continue to manage expenses and cash burn rate at sustainable levels, its ability to continue to work with lenders to extend, repay or refinance indebtedness, or to obtain additional financing, in either case on acceptable terms, continued acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its systems and the timing of such purchases, competitive factors, changes resulting from healthcare reform in the United States, including changes in government reimbursement procedures, dependence upon third-party vendors, timing of regulatory approvals, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments in any particular period or at all because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control. In addition, these orders and commitments may be revised, modified, delayed or canceled, either by their express terms, as a result of negotiations, or by overall project changes or delays.

Company Contact:
Martin C. Stammer
Chief Financial Officer
314-678-6155

Investor Contact:	
Todd Kehrli / Jim Byers
MKR Group, Inc.
323-468-2300
[email protected]